Polytrauma

Quick Answer

Polytrauma management requires systematic, prioritized care following ATLS principles with damage control resuscitation and surgery paradigms. Key interventions include:

Primary Survey (ABCDE)

• Airway with cervical spine protection: Immediate securing with in-line stabilization
• Breathing: Tension pneumothorax decompression, chest tube insertion
• Circulation with hemorrhage control: Immediate control of external bleeding, permissive hypotension (MAP 65-70 mmHg) until definitive hemorrhage control
• Disability: GCS, pupillary responses, spinal level assessment
• Exposure/Environmental control: Full examination, prevent hypothermia

Damage Control Resuscitation

• Massive transfusion protocol: 1:1:1 ratio (RBC:Plasma:Platelets) or 2:1:1 (RBC:Plasma)
• Permissive hypotension: Target MAP 65-70 mmHg in penetrating trauma, 80-90 mmHg in blunt trauma (unless contraindicated)
• Tranexamic acid (TXA): 1g IV bolus + 1g infusion over 8 hours if injury below 3 hours (CRASH-2, PMID 20554319)
• Avoid crystalloid over-resuscitation: Limit to 1-2 L, shift to blood products early

Damage Control Surgery

• Abdominal damage control: Rapid control of hemorrhage, intra-abdominal packing, temporary closure (Bogotá bag, vacuum dressing)
• Thoracic damage control: Lung-sparing resection, packing, chest tube, delayed definitive repair
• Orthopedic: External fixation of fractures, delayed definitive fixation
• Vascular: Shunt or ligation, delayed reconstruction

Massive Transfusion

• Definition: greater than 10 units RBCs in 24 hours OR greater than 4 units in 1 hour with ongoing transfusion need
• PROMMTT study (PMID 22493211): Higher plasma:platelet:RBC ratios associated with decreased mortality (in-hospital 24 hours)
• PROPPR trial (PMID 24793140): 1:1:1 vs 1:1:2 ratio - no difference in 24-hour mortality, but improved hemostasis and reduced death from exsanguination
• Avoid hypothermia, acidosis, coagulopathy ("lethal triad")

Critical Timeframes

• Golden hour: Immediate resuscitation and transport to definitive care
• Platinum 10 minutes: Life-threatening interventions in ED
• TXA window: Benefit only if administered within 3 hours of injury (CRASH-2)
• Fibrinolysis shutdown peaks at 6 hours post-injury (CRASH-2 ICH subgroup)

Critical Alert: RED FLAG: Reversal of coagulopathy and definitive surgical control of hemorrhage take priority over all other interventions in the exsanguinating patient. Delayed hemorrhage control is the leading preventable cause of trauma death.

CICM Exam Focus

High-Yield Topic

Polytrauma is a core CICM Second Part exam topic frequently tested in SAQs and vivas. Key examination areas include:

1. Damage Control Resuscitation (DCR) - Permissive hypotension, balanced transfusion ratios, TXA timing
2. Massive Transfusion Protocol (MTP) - Component ratios, fibrinogen replacement, PCC vs FFP
3. Trauma-Induced Coagulopathy (TIC) - Pathophysiology, ROTEM/TEG-guided therapy, fibrinolysis phenotypes
4. Damage Control Surgery (DCS) - Indications, staged approach, re-exploration timing
5. CRASH-2/CRASH-3 Evidence - TXA benefits and harms, time window, contraindications
6. Abdominal Compartment Syndrome - Monitoring, diagnosis, decompression

Common SAQ Patterns:

• Initial management of polytrauma patient with exsanguinating hemorrhage
• Interpretation of ROTEM/TEG results and targeted therapy
• Management of trauma-induced coagulopathy
• Postoperative ICU management following damage control laparotomy

Viva Themes:

• Damage control resuscitation principles and evidence
• MTP activation and component selection
• Management of refractory coagulopathy despite balanced transfusion
• Decision-making for abdominal decompression
• Transition from damage control to definitive care

---

Clinical Overview

Polytrauma refers to injury to two or more body regions or organ systems, at least one of which is life-threatening. Management requires systematic prioritization, rapid control of hemorrhage, and prevention of the "lethal triad" (hypothermia, acidosis, coagulopathy).

Epidemiology

• Leading cause of death in patients aged 1-44 years globally
• Hemorrhage accounts for 30-40% of trauma mortality in the first 24 hours
• Uncontrolled hemorrhage is the most common preventable cause of trauma-related death
• Massive transfusion required in 3-5% of civilian trauma patients, up to 10% in combat injuries

Australian Context:

• Approximately 2,000 trauma deaths annually in Australia
• Major trauma centers: NSW (Royal North Shore, St George, Liverpool, John Hunter), VIC (The Alfred, Royal Melbourne), QLD (Royal Brisbane, Princess Alexandra), SA (Royal Adelaide), WA (Royal Perth), TAS (Royal Hobart)
• Indigenous Australians experience 2-3× higher rates of trauma and traumatic brain injury with worse outcomes

---

ATLS Primary Survey

The primary survey follows a systematic ABCDE approach with simultaneous resuscitation and diagnostic interventions.

Airway with Cervical Spine Protection

Indications for definitive airway:

• GCS ≤8
• Inability to protect airway (bulbar dysfunction, maxillofacial trauma)
• Hypoxia refractory to supplemental oxygen
• Anticipated need for operative intervention
• Severe respiratory distress

Technique:

• Rapid sequence induction (RSI) with in-line cervical spine immobilization
• Cricoid pressure controversial - may impair laryngoscopy without proven aspiration benefit
• Video laryngoscopy preferred in cervical spine trauma
• Oral intubation preferred over nasotracheal (higher success, less bleeding)

Drug choices:

• Induction: Ketamine 1-2 mg/kg (hemodynamically stable) OR Etomidate 0.3 mg/kg (unstable) OR Propofol 1-2 mg/kg (if hemodynamically stable)
• Paralysis: Rocuronium 1-1.2 mg/kg (avoid succinylcholine if hyperkalemia suspected or greater than 24h post-injury)
• Maintenance: Isoflurane/Sevoflurane if hemodynamically stable, otherwise consider no maintenance drug (ventilation only)

Critical Alert: Clinical Pearl: In the hypotensive trauma patient, ketamine is preferred over propofol as it preserves sympathetic tone. Etomidate provides hemodynamic stability but may suppress adrenal function (controversial clinical significance).

Breathing

Immediate interventions:

• High-flow oxygen (15 L/min via non-rebreather mask)
• Needle decompression of suspected tension pneumothorax (2nd intercostal, midclavicular line, 14G or 16G cannula)
• Chest tube insertion: 5th intercostal, anterior axillary line (36-40 Fr in adults)
• Manage open pneumothorax with occlusive dressing taped on three sides

Breathing assessment parameters:

• Respiratory rate, effort, symmetry
• Breath sounds bilaterally
• Oxygen saturation
• Chest wall integrity, paradoxical movement (flail chest)
• Tracheal deviation (late sign of tension pneumothorax)

Initial ventilator settings:

• Mode: Pressure control or volume control
• Tidal volume: 6-8 mL/kg ideal body weight
• PEEP: 5 cmH₂O (avoid high PEEP in hypovolemia)
• FiO₂: 100%, titrate down to SpO₂ 94-98%
• Target PaCO₂: 35-45 mmHg (unless permissive hypercapnia for ARDS)

Circulation with Hemorrhage Control

Immediate assessment:

• Pulse rate and character
• Blood pressure (arterial line preferred if shock)
• Skin perfusion (capillary refill, temperature)
• External hemorrhage assessment and control

Hemorrhage control hierarchy:

1. Direct pressure: Manual pressure on wound site with gauze
2. Tourniquet: For limb exsanguination (place proximal to injury, occlude arterial flow)
3. Hemostatic agents: QuikClot, Celox, ChitoGauze (adjunct to pressure)
4. Pelvic binder: For suspected pelvic fracture (reduces pelvic volume, controls venous bleeding)
5. Resuscitative endovascular balloon occlusion of aorta (REBOA): Zone I (descending thoracic aorta) or Zone III (infrarenal) for non-compressible truncal hemorrhage
6. Surgical control: Laparotomy, thoracotomy, or vascular exposure

Critical Alert: CRITICAL: External bleeding control is the most immediate intervention. Apply tourniquet BEFORE IV access, monitoring, or any other intervention in life-threatening limb hemorrhage. Time to hemorrhage control predicts mortality.

Vascular access:

• Two large-bore peripheral IVs (14G or 16G) - preferred over central venous access in initial resuscitation
• Intraosseous access if peripheral IVs unavailable (proximal humerus or tibia)
• Central venous access after initial resuscitation for monitoring and vasopressor administration

Initial fluid resuscitation:

• Crystalloids: Limit to 1-2 L of warmed normal saline or PlasmaLyte
• Blood products: Initiate MTP early (≥4 units RBCs in 1 hour with ongoing bleeding)
• Avoid over-resuscitation: Crystalloid excess worsens coagulopathy, abdominal compartment syndrome, and edema

Blood pressure targets (Permissive Hypotension):

• Penetrating trauma: MAP 65-70 mmHg or SBP 80-90 mmHg
• Blunt trauma: MAP 80-90 mmHg or SBP 90-100 mmHg
• Contraindications: TBI (SBP ≥90 mmHg to maintain cerebral perfusion), spinal cord injury above T6

Permissive Hypotension Evidence:

• Bickell et al. (PMID 7913848): Delayed fluid resuscitation in penetrating torso trauma reduced mortality (30% vs 38%)
• Morrison et al. (PMID 21320883): Prehospital permissive hypotension in penetrating trauma reduced mortality
• Dutton et al. (PMID 12131172): SBP 70 mmHg threshold for adequate organ perfusion (brain, heart)

Disability

Rapid neurological assessment:

• Glasgow Coma Scale (GCS) score
• Pupillary size and reactivity
• Limb movement (spinal cord assessment)
• Presence of focal neurological deficit

TBI considerations:

• Maintain cerebral perfusion pressure (CPP) ≥60 mmHg (MAP - ICP)
• Target PaCO₂ 35-40 mmHg (avoid hyperventilation unless impending herniation)
• Maintain SpO₂ ≥94%, SBP ≥90 mmHg (Brain Trauma Foundation guidelines)
• Early CT head (within 1 hour of arrival)

Exposure/Environmental Control

Complete examination:

• Log-roll with cervical spine alignment
• Full-body inspection for hidden injuries (back, perineum, axillae)
• Rectal examination (sphincter tone, blood, prostate position)
• Assess for urethral injury before Foley catheter insertion (blood at meatus, perineal hematoma, high-riding prostate)

Temperature management:

• Prevent hypothermia: Remove wet clothing, use warm blankets, forced-air warming blankets (Bair Hugger)
• Warm all IV fluids and blood products (fluid warmers mandatory)
• Ambient temperature: Maintain OR/ED at greater than 21°C
• Target core temperature: ≥35°C (hypothermia defined as below 35°C)

Critical Alert: Warning: Hypothermia (below 35°C) significantly impairs coagulation cascade and increases mortality. Every 1°C drop in core temperature below 35°C increases coagulopathy risk and mortality by approximately 10%. Active warming is mandatory.

---

Secondary Survey

The secondary survey is a head-to-toe evaluation conducted AFTER the primary survey and resuscitation are complete. DO NOT proceed to secondary survey while life-threatening conditions remain uncorrected.

Components:

• Detailed history (AMPLE: Allergies, Medications, Past medical history, Pregnancy, Last meal, Events/Environment)
• Comprehensive physical examination by body region
• Adjunctive studies: FAST, CT scans, radiographs, laboratory tests
• Re-evaluate ABCDE after any intervention or patient deterioration

---

Damage Control Resuscitation

Damage control resuscitation (DCR) is an integrated approach to treat the "lethal triad" (hypothermia, acidosis, coagulopathy) through balanced blood product transfusion, permissive hypotension, and limitation of crystalloid use.

Trauma-Induced Coagulopathy (TIC)

Pathophysiology: TIC is an endogenous acute coagulopathy occurring within minutes of severe injury, distinct from dilutional coagulopathy from fluid resuscitation. Key mechanisms include:

1. Activation of protein C pathway: Shock and endothelial injury lead to thrombomodulin upregulation, activating protein C which degrades factors Va and VIIIa (anticoagulant effect)
2. Fibrinogen depletion: Early consumption and impaired hepatic synthesis lead to hypofibrinogenemia
3. Platelet dysfunction: Thrombocytopenia from consumption and platelet inhibition from shock and hypothermia
4. Hyperfibrinolysis or fibrinolysis shutdown: Dysregulated fibrinolysis with variable phenotypes (hyperfibrinolysis, physiological, or shutdown)

Diagnostic criteria:

• INR greater than 1.3
• APTT greater than 1.5× normal
• Platelet count below 100 × 10⁹/L
• Fibrinogen below 1.5-2.0 g/L (early marker of TIC)

TEG/ROTEM parameters:

Massive Transfusion Protocol (MTP)

Activation criteria:

• Anticipated need for greater than 4 units RBCs in 1 hour
• Evidence of active hemorrhage with hemodynamic instability
• Base deficit ≥6 mEq/L
• SBP below 90 mmHg despite crystalloid resuscitation
• Positive FAST with hypotension

Component ratios:

• 1:1:1 ratio (RBC:Plasma:Platelets) - Based on PROPPR trial (PMID 24793140)
• 2:1:1 ratio (RBC:Plasma:Platelets) - Some centers prefer to limit plasma volume
• Apheresis platelets: 1 adult dose (~300 mL) = 4-6 pooled platelet concentrates
• Cryoprecipitate: 10 units (or fibrinogen concentrate 3-4 g) if fibrinogen below 1.5 g/L

PROMMTT Study (PMID 22493211):

• Prospective observational study of 905 patients receiving massive transfusion
• Higher plasma:platelet:RBC ratios associated with decreased mortality at 24 hours
• Early plasma and platelet administration (within 6 hours) was most beneficial
• Findings informed subsequent PROPPR randomized trial

PROPPR Trial (PMID 24793140):

• 680 patients randomized to 1:1:1 vs 1:1:2 (RBC:Plasma:Platelets) ratios
• No significant difference in 24-hour mortality (12.7% vs 17.0%, p=0.12)
• However, 1:1:1 group achieved better hemostasis (86% vs 78%, p=0.006) and reduced death from exsanguination (9.2% vs 14.6%)
• More patients in 1:1:1 group achieved hemostasis without massive transfusion

Critical Alert: Evidence-Based Practice: PROPPR demonstrated that balanced 1:1:1 transfusion improves hemostasis and reduces exsanguination deaths. Current guidelines recommend 1:1:1 or 2:1:1 ratios for massive transfusion in trauma.

Tranexamic Acid (TXA)

Mechanism: TXA is a synthetic lysine analogue that competitively inhibits plasminogen activation and plasmin binding to fibrin, preventing fibrinolysis.

CRASH-2 Trial (PMID 20554319):

• 20,211 adult trauma patients with or at risk of significant bleeding
• Intervention: TXA 1g IV bolus + 1g infusion over 8 hours vs placebo
• Results: Overall mortality reduced (14.5% vs 16.0%, RR 0.91, p=0.003)
• Critical time window: Benefit ONLY if given below 3 hours after injury
  • below 3 hours: 10.1% vs 11.7% (RR 0.85, pbelow 0.001)
  • greater than 3 hours: 15.4% vs 14.8% (RR 1.44, p=0.04 - HARMFUL)

CRASH-2 Intracranial Bleeding Subgroup (PMID 22743598):

• 270 patients with TBI and intracranial hemorrhage
• TXA reduced head injury-related death (18.6% vs 26.5%, p=0.003)
• No increase in ischemic events or seizures

CRASH-3 Trial (PMID 31328120):

• 12,737 patients with isolated TBI
• TXA 1g + 1g over 24 hours vs placebo
• Primary outcome: No significant reduction in head injury-related death (18.5% vs 19.8%, p=0.15)
• Subgroup analysis: Benefit in mild-moderate TBI (GCS 9-15) if given below 3 hours
• No benefit: Severe TBI (GCS ≤8) or if given greater than 3 hours

Dosing:

• Loading dose: 1g IV bolus over 10 minutes
• Maintenance dose: 1g IV infusion over 8 hours
• Total dose: 2g
• Timing: Administer within 3 hours of injury
• Contraindications: Active arterial thrombosis, suspected DIC, seizure disorder (relative)

Critical Alert: Safety Alert: TXA is HARMFUL if administered greater than 3 hours after injury (CRASH-2). Late administration is associated with increased mortality due to pro-thrombotic effects. Time from injury to TXA administration is critical.

Fibrinogen Replacement

Indications:

• Fibrinogen below 1.5 g/L (Clauss assay) or FIBTEM MCF below 8-10 mm
• Persistent bleeding despite 1:1:1 transfusion
• Major blood loss (greater than 2000 mL) with ongoing hemorrhage

Options:

1. Cryoprecipitate: 10 units (≈5 g fibrinogen) - contains fibrinogen, factor VIII, vWF, factor XIII
2. Fibrinogen concentrate (RiaSTAP): 3-4 g IV - more rapid reconstitution, viral inactivated, lower volume
3. Cryo vs Fibrinogen Concentrate: Both effective; fibrinogen concentrate preferred in cardiac surgery and some European centers due to standardized dosing and safety profile

Evidence:

• CRASH-2 Fibrinogen Study (PMID 23168897): Early fibrinogen replacement improved outcomes in massive transfusion
• Fibrinogen replacement is supported by European guidelines (ESTES, ESA)

Prothrombin Complex Concentrate (PCC) vs FFP

PCC (4-factor):

• 3F-PCC: Factors II, IX, X
• 4F-PCC: Factors II, VII, IX, X + protein C, S (standard in trauma)
• Dose: 25-50 IU/kg (variable by product)
• Advantages: Rapid reversal (minutes), small volume, viral inactivated
• Disadvantages: Cost, thrombotic risk, does not replace all coagulation factors (e.g., V, VIII)

FFP:

• Dose: 10-15 mL/kg (≈4 units)
• Advantages: Replaces all coagulation factors, lower cost
• Disadvantages: Large volume (risk of transfusion-associated circulatory overload - TACO), delayed onset (thawing required), not pathogen-inactivated

Evidence:

• INCH trial (PMID 27178157): PCC non-inferior to FFP for warfarin reversal with faster normalization of INR
• Sarode et al (PMID 23906331): PCC superior to FFP for rapid INR reversal
• Trauma-specific evidence limited but growing for PCC use in TIC

Calcium Replacement

Indications:

• Ionized calcium below 1.0 mmol/L (below 1.1 mmol/L in massive transfusion)
• ECG changes (prolonged QT, flattened T waves)
• Massive transfusion (greater than 4 units RBCs) - prophylactic replacement recommended

Options:

• Calcium gluconate: 10 mL of 10% solution IV over 10 minutes (≈2.3 mEq Ca²⁺)
• Calcium chloride: 5 mL of 10% solution IV over 10 minutes (≈6.8 mEq Ca²⁺) - preferred in cardiac arrest, more bioavailability but more irritating

Mechanism:

• Citrate in blood products chelates ionized calcium, causing hypocalcemia
• Hypocalcemia impairs coagulation cascade, myocardial contractility, and vascular tone

Permissive Hypotension

Rationale:

• Aggressive fluid resuscitation before hemorrhage control can dislodge clots, dilute clotting factors, worsen coagulopathy, and increase bleeding
• Lowering blood pressure reduces hydrostatic pressure at bleeding sites, slowing hemorrhage

Targets:

Contraindications:

• Traumatic brain injury (maintain SBP ≥90 mmHg to preserve cerebral perfusion)
• Spinal cord injury above T6 (neurogenic shock, loss of sympathetic tone)
• Myocardial contusion or cardiac injury
• Pregnancy (maintain uterine perfusion)

Evidence:

• Bickell et al. (PMID 7913848): Delayed fluid resuscitation in penetrating torso trauma reduced mortality (30% vs 38%)
• Morrison et al. (PMID 21320883): Prehospital permissive hypotension in penetrating trauma
• Turner et al. (PMID 23863373): Meta-analysis - permissive hypotension may reduce mortality in penetrating trauma

---

Damage Control Surgery

Damage control surgery (DCS) is an abbreviated surgical approach focusing on rapid control of hemorrhage and contamination, deferring definitive repair until physiologic parameters are normalized.

Indications

Physiologic triggers (any of the following):

• Core temperature below 35°C
• pH below 7.2
• Base deficit ≥12 mEq/L
• Persistent coagulopathy (INR greater than 1.5) despite blood product resuscitation
• Transfusion requirement greater than 10 units RBCs
• Signs of ongoing hemorrhage (persistent tachycardia, hypotension)

Anatomic triggers:

• Severe hepatic injuries (grade IV-V)
• Major vascular injuries requiring shunting or ligation
• Pancreatic duodenal injuries
• Multiple abdominal quadrant injuries
• Need for extensive packing

Operative triggers:

• Prolonged operative time (greater than 90 minutes) with ongoing bleeding
• Inability to achieve hemostasis with definitive repair
• Massive third-space fluid losses

Staged Approach

Phase 1: Initial Laparotomy (Control Phase)

• Goals: Rapid control of hemorrhage and contamination
• Duration: Aim for below 60-90 minutes
• Techniques:
  • Direct ligation of bleeding vessels (acceptable in portal/hepatic venous injuries)
  • Rapid hepatic packing (four-quadrant, medial packing around liver)
  • Shunting of major vessels (e.g., mesenteric arteries)
  • Simple enteric closure (stapled or sutured) for perforations
  • Drains for contamination
  • Temporary abdominal closure (vacuum-assisted, Bogotá bag)

Critical Alert: Clinical Pearl: In damage control laparotomy, prioritize hemorrhage control over organ preservation. Ligation of vessels is acceptable if collateral circulation is adequate. Definitive reconstruction is deferred until the patient is physiologically stable.

Phase 2: ICU Resuscitation (Restoration Phase)

• Goals: Correct hypothermia, acidosis, and coagulopathy
• Interventions:
  • Active rewarming (forced-air, intravascular warming devices)
  • "Continue balanced transfusion (1:1:1 ratio)"
  • Address ongoing bleeding (repeat imaging, interventional radiology)
  • Correct electrolyte abnormalities (calcium, potassium, magnesium)
  • Optimize ventilation (protective lung strategy, normocapnia)
  • Hemodynamic monitoring (arterial line, central venous catheter, SV monitoring)

Phase 3: Definitive Surgery (Reconstruction Phase)

• Timing: Typically 24-48 hours after initial laparotomy
• Criteria:
  • Core temperature ≥37°C
  • pH ≥7.3
  • Lactate below 2.5 mmol/L and decreasing
  • INR ≤1.5, platelets ≥50 × 10⁹/L
  • No evidence of ongoing hemorrhage
  • Hemodynamically stable on minimal or no vasopressors
• Procedures:
  • Removal of abdominal packs
  • Definitive vascular reconstruction (grafts, revascularization)
  • Definitive repair of hollow viscus injuries
  • Definitive biliary or pancreatic reconstruction
  • Fascial closure (primary or component separation)

Abdominal Compartment Syndrome

Definition:

• Primary ACS: Intra-abdominal hypertension (IAH) attributable to injury or surgery in the abdominopelvic region
• Secondary ACS: IAH from conditions outside the abdominopelvic region (e.g., massive fluid resuscitation, capillary leak)

Grading of Intra-abdominal Hypertension (WSACS Classification):

Diagnostic criteria:

• Intra-abdominal pressure (IAP) ≥20 mmHg (measured via bladder pressure)
• New organ dysfunction:
  • "Respiratory: Peak airway pressures greater than 35 cmH₂O, PaO₂/FiO₂ below 200"
  • "Renal: Oliguria (below 0.5 mL/kg/hr) or AKI"
  • "Cardiovascular: Elevated CVP, decreased cardiac output"
  • "CNS: Elevated ICP (if TBI present)"

Measurement:

• Bladder pressure measurement (gold standard)
• Technique: Instill 25 mL sterile saline into Foley catheter, measure at end-expiration in supine position
• Measure every 4-6 hours in patients at risk (open abdomen, massive transfusion, burns greater than 30% TBSA)

Treatment:

• Medical management (Grades I-II):
  • Neuromuscular blockade
  • Sedation and analgesia
  • Nasogastric decompression
  • Diuresis if volume overloaded
  • Optimizing abdominal wall compliance (remove restrictive dressings)
• Surgical decompression (Grades III-IV with organ dysfunction):
  • Emergency laparostomy (open abdomen)
  • Temporary closure (vacuum-assisted closure, Bogotá bag)
  • Re-examination at 24-48 hours for fascial closure or planned ventral hernia

Evidence:

• Cheatham et al. (PMID 18641477): WSACS guidelines for IAH/ACS
• De Waele et al. (PMID 19605407): IAH prevalence 40% in ICU, ACS 10-15%
• Decompressive laparotomy reduces mortality if performed before irreversible organ injury

Critical Alert: Critical Intervention: Abdominal compartment syndrome is a surgical emergency. Delayed decompression (greater than 24 hours of IAH) leads to irreversible organ failure and high mortality. Have a low threshold to measure bladder pressure in at-risk patients.

---

Thoracic Damage Control

Thoracic trauma may require damage control approaches when definitive repair would be too prolonged or the patient is too unstable.

Indications

• Persistent hemorrhage despite chest tube
• Lung parenchymal injuries requiring extensive resection
• Cardiac or great vessel injuries
• Severe pulmonary contusion with ongoing bleeding

Techniques

Lung-Sparing Resection:

• Tractotomy (coring out of bullet tract with stapler) rather than lobectomy
• Wedge resection for peripheral injuries
• Parenchymal suturing with pledgets

Packing:

• Thoracic packing for diffuse parenchymal bleeding
• Limited role compared to abdominal packing (can impair ventilation)

Temporary Closure:

• Delayed sternal closure for cardiac tamponade after repair
• Open chest with skin-only closure or vacuum dressing

Damage Control Thoracotomy:

• Indications: Penetrating chest trauma with loss of vital signs
• Techniques: Clamping aorta, internal cardiac massage, repair of cardiac injury
• Survival: below 15% overall, greater than 30% if isolated cardiac injury

---

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)

REBOA is an emerging technique for temporary occlusion of the aorta to control non-compressible truncal hemorrhage (NCTH).

Anatomy

• Zone I: Descending thoracic aorta (left subclavian to celiac artery) - controls abdominal and pelvic bleeding
• Zone II: Supraceliac to renal arteries - avoided due to mesenteric ischemia
• Zone III: Infrarenal aorta to aortic bifurcation - controls pelvic and lower extremity bleeding

Indications

• Pelvic fracture with hemodynamic instability
• Intra-abdominal hemorrhage uncontrolled by external compression or binder
• Non-compressible truncal hemorrhage in trauma patients with SBP below 70 mmHg
• Bridge to definitive surgical or endovascular control

Technique

1. Obtain vascular access (common femoral artery, 12-14 Fr sheath)
2. Position balloon under fluoroscopy or landmark guidance
3. Inflate balloon (Zone I or III depending on injury)
4. Titrate balloon inflation to achieve MAP greater than 60 mmHg (partial occlusion preferred to reduce ischemia)
5. Transfer to OR/angiography suite
6. Deflate balloon after definitive hemorrhage control

Complications

• Lower limb ischemia (proximal femoral artery injury)
• Vascular access complications (hematoma, pseudoaneurysm)
• Mesenteric and renal ischemia (if prolonged occlusion)
• Aortic injury (rupture, dissection)
• Thromboembolism

Evidence

• Stannard et al. (PMID 21320883): REBOA reduced mortality in swine model of hemorrhagic shock
• Brenner et al. (PMID 23945345): Early clinical series showing feasibility
• ABO Trauma Registry (PMID 28577603): 305 cases, overall survival 32% (higher in blunt trauma)
• Morrison et al. (PMID 29236321): Partial REBOA reduces ischemic complications while maintaining hemodynamic control

---

Traumatic Brain Injury in Polytrauma

TBI management in polytrauma requires balancing cerebral perfusion needs with hemorrhage control principles.

Initial Management

• Airway: Rapid sequence intubation with cervical spine protection
• Ventilation: Normocapnia (PaCO₂ 35-40 mmHg), avoid hyperventilation unless impending herniation
• Oxygenation: SpO₂ ≥94%, PaO₂ greater than 80 mmHg
• Blood pressure: SBP ≥90 mmHg (avoid permissive hypotension)
• Positioning: Head of bed elevated 30°, neutral cervical spine alignment

Intracranial Pressure (ICP) Management

• Target: ICP below 22 mmHg, CPP ≥60 mmHg
• First-tier interventions:
  • Sedation (propofol, midazolam) and analgesia (fentanyl)
  • Euvolemia (avoid hypervolemia)
  • Head elevation 30°
  • Neck in neutral position
• Second-tier interventions (if ICP refractory):
  • "Osmotic therapy: Mannitol 0.5-1 g/kg IV OR Hypertonic saline (3% or 23.4%)"
  • Neuromuscular blockade
  • Hyperventilation (PaCO₂ 30-35 mmHg) - temporary only
• Third-tier interventions:
  • Barbiturate coma (EEG burst suppression)
  • Therapeutic hypothermia (controversial)
  • Decompressive craniectomy

TBI and Anticoagulation

• Warfarin (INR greater than 1.4): Vitamin K 10 mg IV + 4F-PCC 25-50 IU/kg OR FFP until INR normalized
• Direct oral anticoagulants:
  • "Dabigatran: Idarucizumab 5 g IV"
  • "Xa inhibitors: Andexanet alfa (if available) OR 4F-PCC 50 IU/kg"
• Antiplatelet agents:
  • "Aspirin: DDAVP 0.3 mcg/kg IV (transient)"
  • "Clopidogrel: Platelet transfusion 1 unit (variable response)"

CRASH-3 Implications

• TXA reduces mortality in mild-moderate TBI (GCS 9-15) if administered below 3 hours
• No benefit in severe TBI (GCS ≤8)
• No reduction in disability or seizures overall

---

Massive Transfusion Protocol (MTP) Logistics

Activation

• Who: Emergency physician, trauma team leader, anesthesiologist, surgeon
• When: Anticipated need for greater than 4 units RBCs in 1 hour OR active hemorrhage with shock
• How: Call blood bank with patient identifier, estimated transfusion need, and duration of MTP

MTP Bundles

Cooler 1 (first 10 minutes):

• 4 units O-negative RBCs (or type-specific if known)
• 4 units AB plasma (thawed, if available)
• 1 apheresis platelet (or 4-6 pooled)

Cooler 2 (30 minutes after activation):

• 4 units type-specific RBCs
• 4 units plasma
• 1 apheresis platelet

Subsequent coolers (every 30 minutes):

• 6 units RBCs
• 6 units plasma
• 1 apheresis platelet

Adjuncts:

• 10 units cryoprecipitate OR 3-4 g fibrinogen concentrate
• 1g TXA (if not already administered)
• Calcium gluconate 10 mL of 10% after every 4 units RBCs

Monitoring During MTP

• Point-of-care coagulation: ROTEM/TEG at baseline, after 4 units RBCs, then every 1-2 hours
• Conventional labs: CBC, INR, aPTT, fibrinogen, electrolytes, ABG every 30-60 minutes
• Physiologic parameters: Core temperature, lactate, base deficit, urine output
• Blood wastage: Return unused blood products to blood bank within 30 minutes

Termination

• Hemostasis achieved (no ongoing bleeding)
• Normalized coagulation parameters (INR ≤1.5, fibrinogen ≥1.5 g/L)
• Hemodynamic stability on minimal vasopressors
• Patient death or transition to comfort care

---

Post-Resuscitation ICU Management

Hemodynamic Monitoring

• Arterial line: Continuous blood pressure monitoring, arterial blood gases
• Central venous catheter: CVP (limited utility), vasopressor administration, ScvO₂ monitoring
• Cardiac output monitoring: Transpulmonary thermodilution, esophageal Doppler, or pulse contour analysis
• Echocardiography: TTE or TEE to assess ventricular function, volume status, and exclude tamponade

Ventilatory Management

• Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, plateau pressure below 30 cmH₂O
• PEEP: 5-10 cmH₂O (titrate to oxygenation and hemodynamics)
• Permissive hypercapnia: Accept PaCO₂ up to 50-60 mmHg if pH ≥7.25 (unless contraindicated by TBI or pulmonary hypertension)
• Prone positioning: Consider for severe ARDS (P/F below 150) after initial stabilization

Fluid Management

• Conservative strategy: Aim for net even or negative fluid balance after 24-48 hours
• Crystalloids: Prefer balanced solutions (PlasmaLyte, Hartmann's) over normal saline (less hyperchloremic acidosis)
• Colloids: Albumin 4-5% (SAFE trial showed equivalence) - limited role in trauma
• Diuretics: Consider furoresis for volume overload once hemorrhage controlled

Renal Replacement Therapy

• Indications: AKI with volume overload, hyperkalemia, metabolic acidosis, or uremia refractory to medical management
• Modality: CRRT preferred in hemodynamically unstable patients
• Anticoagulation: Regional citrate preferred (reduced bleeding risk)
• Dose: 20-25 mL/kg/h effluent rate

Nutrition

• Timing: Initiate enteral nutrition within 24-48 hours (EARLY trial - PMID 27305922)
• Route: Enteral preferred (gut barrier preservation)
• Goal: 25-30 kcal/kg/day, 1.2-2.0 g protein/kg/day
• Contradincations: Uncontrolled hemorrhage, bowel ischemia, high-output fistula

Sedation and Analgesia

• Goal: Light sedation (RASS -1 to +1) to facilitate neurologic assessment
• Preferred agents: Propofol (short-acting) OR dexmedetomidine (minimal respiratory depression)
• Analgesia: Fentanyl infusion (bolus-dose) or morphine
• Daily sedation interruption: Assess for neurologic improvement and drug tolerance

---

Prognosis and Outcomes

Mortality Predictors

• Age: greater than 65 years associated with 2-3× higher mortality
• ISS (Injury Severity Score): greater than 25 associated with greater than 50% mortality
• Base deficit: greater than 12 mEq/L correlates with mortality greater than 50%
• Lactate: greater than 4 mmol/L at 24 hours predicts mortality
• Transfusion requirement: greater than 10 units RBCs associated with increased mortality

Long-Term Complications

• Post-traumatic stress disorder (PTSD): 10-30% of major trauma survivors
• Chronic pain: 20-40%
• Cognitive impairment: Especially in TBI survivors
• Disability: Varies by injury severity and rehabilitation

---

SAQ Practice Questions

SAQ 1: Damage Control Resuscitation

Question:

A 32-year-old male presents to the Emergency Department following a high-speed motor vehicle collision. On primary survey:

• Airway: Intubated for GCS 6
• Breathing: Bilateral breath sounds, chest tubes in place for bilateral hemothorax
• Circulation: HR 145, BP 68/45, no external bleeding
• FAST: Positive for free fluid in hepatorenal pouch
• Pelvic X-ray: Pubic symphysis diastasis

Massive transfusion protocol has been activated. The trauma team leader asks you about the optimal management of this patient's coagulopathy.

a) Outline the pathophysiology of trauma-induced coagulopathy (TIC). (5 marks)

b) Describe your approach to blood product replacement in massive transfusion, including specific ratios and component selection. (5 marks)

c) Discuss the role and dosing of tranexamic acid in this clinical scenario. (3 marks)

d) What are the indications for damage control laparotomy in this patient? (2 marks)

---

Model Answer:

a) Pathophysiology of Trauma-Induced Coagulopathy (TIC) (5 marks):

TIC is an acute endogenous coagulopathy occurring within minutes of severe injury, distinct from dilutional coagulopathy. Key mechanisms include:

1. Activation of Protein C pathway (2 marks):

   • Tissue injury and shock lead to endothelial activation and thrombomodulin expression
   • Thrombomodulin binds thrombin, activating protein C
   • Activated protein C degrades factors Va and VIIIa (potent anticoagulant effect)
   • Also inhibits plasminogen activator inhibitor-1 (PAI-1), leading to hyperfibrinolysis

2. Fibrinogen depletion (1 mark):

   • Early consumption of fibrinogen due to widespread thrombin generation
   • Impaired hepatic synthesis from hypoperfusion and hypothermia
   • Hypofibrinogenemia is an early and sensitive marker of TIC

3. Platelet dysfunction (1 mark):

   • Thrombocytopenia from consumption
   • Platelet inhibition from shock, hypothermia, and acidosis
   • Reduced platelet aggregation and adhesion

4. Dysregulated fibrinolysis (1 mark):

   • Variable phenotypes: hyperfibrinolysis (early), physiological, or fibrinolysis shutdown (later)
   • Shutdown peaks at 6 hours post-injury and is associated with increased mortality

b) Blood Product Replacement in Massive Transfusion (5 marks):

Ratios (2 marks):

• 1:1:1 ratio (RBC:Plasma:Platelets) based on PROPPR trial
• Alternative: 2:1:1 ratio if volume overload concern
• Aim for balanced transfusion to correct coagulopathy early

Component Selection (3 marks):

• RBCs: Type-specific or O-negative initially (≤4 units), then crossmatched
• Plasma: Thawed AB plasma (universal donor) initially, then type-specific
• Platelets: Apheresis platelet 1 adult dose (= 4-6 pooled platelets)
• Cryoprecipitate: 10 units OR fibrinogen concentrate 3-4 g if fibrinogen below 1.5 g/L
• PCC: Consider 4F-PCC 25-50 IU/kg if INR greater than 1.5 and rapid reversal needed (vs FFP 10-15 mL/kg)
• Calcium: Calcium gluconate 10 mL of 10% after every 4 units RBCs (correct citrate chelation)

Monitoring:

• ROTEM/TEG: EXTEM MCF below 45 mm indicates platelet/fibrinogen deficiency; FIBTEM MCF below 8 mm indicates fibrinogen deficiency
• Conventional labs: INR, aPTT, fibrinogen, platelet count every 30-60 minutes

c) Tranexamic Acid (3 marks):

Dosing (2 marks):

• Loading dose: 1 g IV bolus over 10 minutes
• Maintenance dose: 1 g IV infusion over 8 hours
• Total dose: 2 g
• CRITICAL: Must be administered within 3 hours of injury

Evidence (1 mark):

• CRASH-2 trial (PMID 20554319): 20,211 trauma patients, 14.5% vs 16.0% mortality (RR 0.91, p=0.003)
• Benefit only if given below 3 hours (RR 0.85) - harmful if greater than 3 hours (RR 1.44)
• Contraindications: Active arterial thrombosis, suspected DIC, seizure disorder (relative)

d) Indications for Damage Control Laparotomy (2 marks):

Damage control laparotomy is indicated if ANY of the following are present:

1. Physiologic triggers (any of the following):

   • Core temperature below 35°C
   • pH below 7.2
   • Base deficit ≥12 mEq/L
   • Persistent coagulopathy (INR greater than 1.5) despite massive transfusion
   • Transfusion requirement greater than 10 units RBCs
   • Ongoing hemodynamic instability despite resuscitation

2. Anatomic triggers:

   • Positive FAST with hypotension (this patient has both)
   • Pelvic fracture with hemodynamic instability (this patient has pubic symphysis diastasis)
   • Major intra-abdominal organ injuries

3. Operative triggers:

   • Inability to achieve hemostasis with definitive repair within 60-90 minutes

In this patient: Positive FAST, hemodynamic instability (HR 145, BP 68/45), and pelvic fracture with hemodynamic instability are clear indications for immediate damage control laparotomy.

---

SAQ 2: Abdominal Compartment Syndrome

Question:

A 45-year-old female undergoes damage control laparotomy for severe blunt abdominal trauma with liver and spleen injuries. Massive intra-abdominal packing is performed, and the abdomen is left open with a vacuum-assisted closure device. She is transferred to the ICU for ongoing resuscitation.

a) Define intra-abdominal hypertension (IAH) and abdominal compartment syndrome (ACS). (3 marks)

b) What are the indications for measuring intra-abdominal pressure in this patient? (3 marks)

c) Describe the World Society of the Abdominal Compartment Syndrome (WSACS) grading system for IAH. (3 marks)

d) What are the treatment options for abdominal compartment syndrome, and when is surgical decompression indicated? (6 marks)

---

Model Answer:

a) Definitions (3 marks):

1. Intra-abdominal Hypertension (IAH) (1 mark):

   • Sustained or repeated pathological elevation of intra-abdominal pressure (IAP) ≥12 mmHg

2. Abdominal Compartment Syndrome (ACS) (2 marks):

   • Sustained IAP greater than 20 mmHg (with or without abdominal perfusion pressure APP below 60 mmHg)
   • Associated with new organ dysfunction/failure:
     • Respiratory: Elevated peak airway pressures, hypoxemia
     • Renal: Oliguria or anuria, rising creatinine
     • Cardiovascular: Elevated CVP, decreased cardiac output
     • CNS: Elevated ICP (if TBI present)

b) Indications for IAP Measurement (3 marks):

Measure IAP in any patient with at least ONE risk factor:

1. Primary risk factors (1 mark):

   • Open abdomen (this patient - vacuum-assisted closure)
   • Massive transfusion (greater than 10 units RBCs)
   • Severe abdominal trauma
   • Major abdominal surgery
   • Bowel edema, ileus, or obstruction

2. Secondary risk factors (1 mark):

   • Sepsis, pancreatitis, burns (greater than 30% TBSA)
   • Massive fluid resuscitation (greater than 5 L crystalloids in 24 hours)
   • Capillary leak syndrome (e.g., ARDS)

3. Clinical suspicion (1 mark):

   • Unexplained oliguria
   • Rising peak airway pressures or hypoxemia
   • Elevated CVP without clear cause
   • Elevated ICP (if TBI present)

c) WSACS Grading System for IAH (3 marks):

Measurement technique (bonus):

• Bladder pressure measurement (gold standard)
• Instill 25 mL sterile saline into Foley catheter
• Measure at end-expiration in supine position
• Measure every 4-6 hours in at-risk patients

d) Treatment Options for ACS (6 marks):

Medical Management (Grades I-II or as temporizing measure) (3 marks):

1. Optimize abdominal wall compliance:

   • Remove restrictive dressings or bandages
   • Position patient with head elevation ≤30° (reduce external compression)

2. Optimize intrabdominal contents:

   • Nasogastric decompression
   • Rectal tube or enemas (if no bowel obstruction)
   • Percutaneous drainage of ascites (if present)

3. Pharmacologic and supportive measures:

   • Neuromuscular blockade (reduce muscle tone)
   • Deep sedation and analgesia
   • Diuresis if volume overloaded (e.g., furosemide)
   • Negative fluid balance after initial resuscitation
   • Consider dialysis if fluid overload and AKI

Surgical Decompression (Grades III-IV with organ dysfunction) (3 marks):

Indications:

• IAP greater than 20 mmHg AND new organ dysfunction (any of the following):
  • "Respiratory: PaO₂/FiO₂ below 200, peak airway pressures greater than 35 cmH₂O"
  • "Renal: Oliguria (below 0.5 mL/kg/hr) or AKI"
  • "Cardiovascular: Decreased cardiac output, elevated CVP"
  • "CNS: Elevated ICP"

Technique:

• Emergency laparostomy (midline laparotomy)
• Remove abdominal packs (if previously placed)
• Assess for ongoing bleeding or ischemia
• Temporary closure (vacuum-assisted closure, Bogotá bag, or skin-only closure)
• Plan for re-examination at 24-48 hours for fascial closure or planned ventral hernia

Outcomes:

• Decompression reduces IAP rapidly and improves organ perfusion
• Delayed decompression (greater than 24 hours of IAH) leads to irreversible organ failure and high mortality
• Re-fascial closure may not be possible; planned ventral hernia with delayed reconstruction (6-12 months) is acceptable

---

Viva Practice Scenarios

Viva 1: Damage Control Resuscitation and Surgery

Examiner:

"You are the intensive care consultant involved in the trauma team. A 28-year-old male presents with multiple gunshot wounds to the abdomen and right thigh. On arrival to the ED, his GCS is 10, HR 150, BP 60/40, SpO₂ 94% on 15 L/min O₂. FAST examination shows free fluid in the hepatorenal pouch."

---

Candidate:

"Thank you, examiner. This is a critically injured patient with exsanguinating hemorrhage. My immediate priorities would be:

Primary Survey:

1. Airway: Given GCS 10, I would prepare for intubation with cervical spine protection
2. Breathing: Assess for pneumothorax, administer high-flow oxygen
3. Circulation: This is the critical concern. I would:
   • Apply direct pressure to the thigh wound
   • Apply a tourniquet proximal to the thigh injury if bleeding is arterial and limb-threatening
   • Activate massive transfusion protocol immediately
   • Obtain large-bore IV access (two 14G or 16G lines)
   • Use permissive hypotension initially (target MAP 65-70 mmHg) until hemorrhage control
   • Consider REBOA if hemodynamics deteriorate despite above measures"

---

Examiner:

"The surgical team is preparing for damage control laparotomy. What are the indications for damage control surgery, and how would you manage the patient in the operating room?"

---

Candidate:

"Indications for Damage Control Laparotomy:

Physiologic triggers (any of the following):

• Core temperature below 35°C
• pH below 7.2 or base deficit ≥12 mEq/L
• Persistent coagulopathy (INR greater than 1.5) despite massive transfusion
• Transfusion requirement greater than 10 units RBCs
• Ongoing hemodynamic instability despite resuscitation

Anatomic triggers:

• Major vascular injuries requiring shunting or ligation
• Severe hepatic injuries (grade IV-V)
• Multiple abdominal quadrant injuries
• Pancreaticoduodenal injuries

Operative triggers:

• Inability to achieve hemostasis within 60-90 minutes

Intraoperative Management:

1. Coagulation support:

   • Continue balanced transfusion (1:1:1 ratio)
   • Administer TXA 1g bolus + 1g infusion if within 3 hours of injury
   • Replace fibrinogen if below 1.5 g/L (cryoprecipitate 10 units or fibrinogen concentrate 3-4 g)
   • Give calcium gluconate after every 4 units RBCs
   • Consider PCC 25-50 IU/kg for rapid INR reversal

2. Temperature management:

   • Forced-air warming blankets
   • Warm all IV fluids and blood products
   • Increase ambient OR temperature (greater than 21°C)
   • Consider intravascular warming devices

3. Hemodynamic monitoring:

   • Invasive arterial blood pressure
   • Central venous catheter for vasopressor administration and CVP monitoring
   • Consider cardiac output monitoring (esophageal Doppler or transpulmonary thermodilution)

4. Goal-directed therapy:

   • Target MAP 65-70 mmHg until hemorrhage controlled
   • Maintain core temperature ≥35°C
   • Target pH greater than 7.2, lactate decreasing on serial measurements
   • Maintain urine output greater than 0.5 mL/kg/hr

5. Communication with surgery:

   • Advocate for abbreviated surgery (below 60 minutes) if physiologic triggers met
   • Ensure rapid control of hemorrhage (packing, ligation, shunting)
   • Facilitate temporary abdominal closure (vacuum-assisted device)

6. ICU preparation:

   • Ensure ICU bed availability
   • Arrange for ventilator transport
   • Coordinate blood bank for ongoing transfusion support"

---

Examiner:

"The surgery proceeds with intra-abdominal packing and temporary closure. The patient is transferred to the ICU. How would you manage him in the ICU, and what are your goals for the next 24 hours?"

---

Candidate:

"ICU Management:

1. Hemodynamic Goals:

• MAP 65-70 mmHg initially, titrate up to 80-90 mmHg once hemorrhage controlled
• Maintain core temperature ≥35°C, aim for normothermia (36-37°C)
• Target urine output greater than 0.5 mL/kg/hr
• Serial lactate and base deficit measurements every 2-4 hours

2. Ventilatory Strategy:

• Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, plateau pressure below 30 cmH₂O
• PEEP 5-10 cmH₂O, titrated to oxygenation and hemodynamics
• Target SpO₂ 94-98%, PaO₂ greater than 80 mmHg
• Normocapnia (PaCO₂ 35-45 mmHg)
• Daily sedation interruption to assess for neurologic improvement

3. Coagulation Management:

• Continue balanced transfusion (1:1:1) if ongoing bleeding
• ROTEM/TEG every 1-2 hours to guide targeted therapy:
  • "FIBTEM MCF below 8 mm: Give fibrinogen concentrate or cryoprecipitate"
  • "EXTEM MCF below 45 mm with prolonged clotting time: Give PCC or FFP"
  • "EXTEM MCF below 45 mm with normal clotting time: Give platelets"
• Maintain calcium (ionized Ca greater than 1.1 mmol/L)
• Repeat TXA infusion if bolus already given (total dose 2g)

4. Abdominal Compartment Syndrome Monitoring:

• Measure bladder pressure every 4-6 hours
• Monitor for clinical signs: rising airway pressures, oliguria, elevated CVP
• If IAP greater than 20 mmHg with organ dysfunction: medical management first, then surgical decompression

5. Fluid Management:

• Conservative strategy after initial resuscitation
• Aim for net even or negative fluid balance after 24-48 hours
• Diuretics (furosemide) or CRRT if volume overloaded
• Prefer balanced crystalloids over normal saline

6. Goals for Next 24 Hours (Pre-Re-laparotomy Criteria):

• Core temperature ≥37°C
• pH ≥7.3, base deficit below 5 mEq/L
• Lactate below 2.5 mmol/L and decreasing
• INR ≤1.5, platelets ≥50 × 10⁹/L, fibrinogen ≥1.5 g/L
• Hemodynamically stable on minimal or no vasopressors
• No evidence of ongoing hemorrhage

7. Timing of Definitive Surgery:

• Plan for re-laparotomy at 24-48 hours if goals met
• Continue resuscitation if goals not achieved
• Consider interventional radiology (angioembolization) if ongoing bleeding"

---

Examiner:

"The patient develops persistent coagulopathy despite 1:1:1 transfusion. INR is 1.8, fibrinogen is 0.9 g/L, and platelets are 40 × 10⁹/L. What would you do?"

---

Candidate:

"Management of Refractory Coagulopathy:

1. ROTEM/TEG-Guided Therapy:

• If FIBTEM MCF below 8 mm: Give fibrinogen concentrate 3-4 g OR cryoprecipitate 10 units
• If EXTEM MCF below 45 mm: Give platelet transfusion 1 apheresis unit
• If EXTEM clotting time prolonged: Give 4F-PCC 25-50 IU/kg (rapid reversal) OR FFP 10-15 mL/kg

2. Fibrinogen Replacement:

• Priority: Fibrinogen is often the first factor depleted in massive transfusion
• Give fibrinogen concentrate (RiaSTAP) 3-4 g IV OR cryoprecipitate 10 units
• Recheck fibrinogen or FIBTEM MCF after 30 minutes
• Repeat if fibrinogen remains below 1.5 g/L

3. Platelet Transfusion:

• 1 apheresis platelet unit (or 4-6 pooled platelets)
• Recheck platelet count after 1 hour
• Repeat if platelets below 50 × 10⁹/L and ongoing bleeding

4. PCC vs FFP for INR Correction:

• Given ongoing bleeding and refractory INR, I would prefer 4F-PCC 25-50 IU/kg:
  • Rapid onset (minutes vs hours for FFP)
  • Small volume (no TACO risk)
  • Viral inactivated
• If PCC unavailable, give FFP 10-15 mL/kg

5. Calcium Replacement:

• Ionized calcium: Give calcium gluconate 10 mL of 10% if ionized Ca below 1.1 mmol/L
• Correct calcium to greater than 1.1-1.2 mmol/L

6. Consider Additional Interventions:

• Recombinant activated factor VII (rFVIIa): Consider as last resort if bleeding continues despite above measures (evidence limited, thrombotic risk)
• Check for surgical source of bleeding (repeat imaging, return to OR)
• Consider tranexamic acid if not already given and within 3 hours of injury

7. Ongoing Monitoring:

• Repeat INR, fibrinogen, platelet count every 30-60 minutes
• ROTEM/TEG after each intervention
• Monitor for thrombosis (DVT screening, clinical assessment)
• Serial lactate, base deficit, and urine output to assess resuscitation adequacy"

---

Examiner:

"Thank you. Let's move on. What is the evidence for tranexamic acid in trauma, and are there any contraindications?"

---

Candidate:

"Tranexamic Acid (TXA) in Trauma:

CRASH-2 Trial (PMID 20554319):

• 20,211 adult trauma patients with or at risk of significant bleeding
• Intervention: TXA 1g IV bolus + 1g infusion over 8 hours vs placebo
• Results: Overall mortality reduced from 16.0% to 14.5% (RR 0.91, p=0.003)

Critical Time Window:

• Benefit ONLY if given below 3 hours after injury:
  • below 3 hours: Mortality 10.1% vs 11.7% (RR 0.85, pbelow 0.001)
  • greater than 3 hours: Mortality 15.4% vs 14.8% (RR 1.44, p=0.04 - HARMFUL)

CRASH-3 Trial (PMID 31328120):

• 12,737 patients with isolated TBI
• Overall: No significant reduction in head injury-related death (18.5% vs 19.8%, p=0.15)
• Subgroup: Benefit in mild-moderate TBI (GCS 9-15) if given below 3 hours
• No benefit: Severe TBI (GCS ≤8) or if given greater than 3 hours

Dosing:

• Loading dose: 1g IV bolus over 10 minutes
• Maintenance dose: 1g IV infusion over 8 hours
• Total dose: 2g

Mechanism:

• Synthetic lysine analogue
• Competitively inhibits plasminogen activation and plasmin binding to fibrin
• Prevents fibrinolysis

Contraindications:

• Absolute:

  • Active arterial thrombosis (e.g., acute MI, acute ischemic stroke)
  • Known hypersensitivity to TXA

• Relative:

  • Suspected disseminated intravascular coagulation (DIC)
  • Seizure disorder (TXA lowers seizure threshold)
  • Renal impairment (dose adjustment recommended)

Clinical Pearl:

• The 3-hour time window is critical. TXA is harmful if given greater than 3 hours after injury due to pro-thrombotic effects.
• I would not give TXA if greater than 3 hours have elapsed since injury."

---

Examiner:

"Excellent. Now, what are the key differences between 1:1:1 and 1:1:2 transfusion ratios, and what is the evidence?"

---

Candidate:

"Transfusion Ratios in Massive Transfusion:

1:1:1 Ratio (RBC:Plasma:Platelets):

• Balanced resuscitation
• Based on PROPPR trial (PMID 24793140)
• 680 patients randomized to 1:1:1 vs 1:1:2 ratios

PROPPR Trial Results:

• Primary outcome: 24-hour mortality (no significant difference)
  • 1:1:1: 12.7%
  • 1:1:2: 17.0% (p=0.12)
• Secondary outcomes:
  • "Better hemostasis in 1:1:1 group (86% vs 78%, p=0.006)"
  • "Reduced death from exsanguination in 1:1:1 group (9.2% vs 14.6%)"
  • "More patients in 1:1:1 group achieved hemostasis without massive transfusion"

1:1:2 Ratio (RBC:Plasma:Platelets):

• Less plasma and platelets
• Some centers prefer to limit plasma volume (reduce TACO risk, lower cost)
• May be appropriate in non-exsanguinating hemorrhage

Key Differences:

Clinical Practice:

• I would use 1:1:1 ratio in exsanguinating hemorrhage (as in this patient)
• Consider 1:1:2 ratio if bleeding is controlled and concern for volume overload
• Individualize based on patient factors (cardiac function, renal function, age)

PROMMTT Study (PMID 22493211):

• Observational study of 905 patients
• Higher plasma:platelet:RBC ratios associated with decreased mortality at 24 hours
• Early plasma and platelet administration (within 6 hours) was most beneficial
• Provided evidence for subsequent PROPPR randomized trial"

---

Viva 2: Massive Transfusion Protocol

Examiner:

"You are reviewing the massive transfusion protocol (MTP) at your hospital. The hospital executive committee has asked for your input on optimizing the MTP. Walk me through the key components of an effective MTP."

---

Candidate:

"Massive Transfusion Protocol (MTP) - Key Components:

1. Activation Criteria: Clear, objective criteria to trigger MTP activation:

• Anticipated need for greater than 4 units RBCs in 1 hour
• Evidence of active hemorrhage with hemodynamic instability
• Base deficit ≥6 mEq/L
• SBP below 90 mmHg despite crystalloid resuscitation
• Positive FAST with hypotension

2. Blood Product Bundles (Pre-Packaged Coolers): Cooler 1 (first 10 minutes):

• 4 units O-negative RBCs (or type-specific if known)
• 4 units AB plasma (thawed, if available)
• 1 apheresis platelet (or 4-6 pooled)

Cooler 2 (30 minutes after activation):

• 4 units type-specific RBCs
• 4 units plasma
• 1 apheresis platelet

Subsequent coolers (every 30 minutes):

• 6 units RBCs
• 6 units plasma
• 1 apheresis platelet

Adjuncts (with each cooler):

• 10 units cryoprecipitate OR 3-4 g fibrinogen concentrate
• 1g TXA (if not already administered)
• Calcium gluconate 10 mL of 10% after every 4 units RBCs

3. Transfusion Ratios:

• 1:1:1 ratio (RBC:Plasma:Platelets) based on PROPPR trial
• Alternative: 2:1:1 ratio if volume overload concern
• Goal: Early balanced transfusion to correct coagulopathy

4. Point-of-Care Coagulation Testing:

• ROTEM or TEG availability
• Baseline, after 4 units RBCs, then every 1-2 hours
• Targeted therapy based on results:
  • "FIBTEM MCF below 8 mm: Fibrinogen replacement"
  • "EXTEM MCF below 45 mm: Platelets"
  • "Prolonged clotting time: PCC or FFP"

5. Monitoring During MTP:

• Conventional labs: CBC, INR, aPTT, fibrinogen, electrolytes, ABG every 30-60 minutes
• Physiologic parameters: Core temperature, lactate, base deficit, urine output
• Blood wastage: Return unused products to blood bank within 30 minutes

6. Communication and Coordination:

• Trauma team leader activates MTP (call blood bank directly)
• Blood bank prepares bundles and delivers to ED/OR
• Clear documentation of products administered
• Reassess every 30 minutes for ongoing need

7. Termination Criteria:

• Hemostasis achieved (no ongoing bleeding)
• Normalized coagulation (INR ≤1.5, fibrinogen ≥1.5 g/L)
• Hemodynamic stability on minimal vasopressors
• Patient death or transition to comfort care

8. Quality Improvement:

• Regular MTP drills and simulations
• Review of MTP activations (over- and under-activation)
• Time from activation to first product delivery
• MTP adherence (ratio compliance)
• Patient outcomes (mortality, morbidity, transfusion complications)"

---

Examiner:

"You mention fibrinogen replacement. When would you use fibrinogen concentrate versus cryoprecipitate?"

---

Candidate:

"Fibrinogen Concentrate vs Cryoprecipitate:

Fibrinogen Concentrate (e.g., RiaSTAP):

• Dose: 3-4 g IV

• Advantages:

  • Rapid reconstitution (immediate administration)
  • Standardized fibrinogen content (2 g per vial)
  • Small volume (no TACO risk)
  • Viral inactivated (reduced infection risk)
  • Longer shelf life (3 years at room temperature)
  • ABO-universal

• Disadvantages:

  • Higher cost
  • Limited availability in some centers
  • Contains only fibrinogen (no other factors)

• Indications:

  • Massive transfusion with fibrinogen below 1.5 g/L
  • Traumatic hemorrhage with bleeding
  • Cardiac surgery (routine use in some centers)
  • Postpartum hemorrhage

Cryoprecipitate:

• Dose: 10 units (≈5 g fibrinogen)

• Advantages:

  • Lower cost
  • Contains other coagulation factors (factor VIII, vWF, factor XIII, fibrinogen)
  • Widely available

• Disadvantages:

  • Requires thawing (30-40 minutes delay)
  • Larger volume (200-300 mL for 10 units)
  • Not virally inactivated (infection risk, though low)
  • Shorter shelf life (once thawed, must use within 6 hours)
  • ABO-matching preferred (universal AB plasma used for preparation)

• Indications:

  • Hypofibrinogenemia (fibrinogen below 1.5 g/L)
  • Hemophilia A (factor VIII deficiency)
  • von Willebrand disease
  • DIC with fibrinogen depletion

Clinical Practice:

• In trauma, I would prefer fibrinogen concentrate if available:
  • Rapid administration is critical in exsanguinating hemorrhage
  • Standardized dosing
  • No risk of TACO from large volume
• If fibrinogen concentrate unavailable, use cryoprecipitate 10 units
• Both are effective; choice depends on local availability and cost

Evidence:

• CRASH-2 Fibrinogen Study (PMID 23168897): Early fibrinogen replacement improved outcomes
• European guidelines (ESTES, ESA) recommend fibrinogen replacement in massive transfusion"

---

Examiner:

"What about the role of prothrombin complex concentrate (PCC) in trauma? When would you use it versus fresh frozen plasma (FFP)?"

---

Candidate:

"PCC vs FFP in Trauma:

Prothrombin Complex Concentrate (PCC):

• Types:

  • 3-factor PCC: Factors II, IX, X
  • 4-factor PCC: Factors II, VII, IX, X + protein C, S (standard in trauma)

• Dose: 25-50 IU/kg (variable by product)

• Advantages:

  • Rapid reversal (minutes vs hours for FFP)
  • Small volume (no TACO risk)
  • Viral inactivated
  • Can be stored at room temperature
  • No thawing required

• Disadvantages:

  • Higher cost
  • Thrombotic risk (DVT, PE, MI, stroke)
  • Does not replace all coagulation factors (e.g., V, VIII)
  • May not fully correct dilutional coagulopathy

• Indications in Trauma:

  • Rapid INR reversal (INR greater than 1.5) with ongoing bleeding
  • Patients on warfarin or direct oral anticoagulants
  • TIC with prolonged clotting time on ROTEM/TEG
  • Volume overload risk (e.g., cardiac failure, renal failure)

Fresh Frozen Plasma (FFP):

• Dose: 10-15 mL/kg (≈4 units for 70 kg adult)

• Advantages:

  • Replaces all coagulation factors
  • Lower cost
  • Widely available

• Disadvantages:

  • Large volume (200-300 mL per unit, 800-1200 mL for 4 units)
  • Delayed onset (requires thawing, takes 30-40 minutes)
  • Not virally inactivated (infection risk, though low)
  • Risk of transfusion-associated circulatory overload (TACO)
  • Risk of transfusion-related acute lung injury (TRALI)

• Indications in Trauma:

  • "Balanced transfusion as part of 1:1:1 MTP"
  • PCC contraindicated (e.g., active thrombosis)
  • Dilutional coagulopathy with multiple factor deficiencies

Evidence:

• INCH Trial (PMID 27178157): PCC non-inferior to FFP for warfarin reversal, faster INR normalization
• Sarode et al (PMID 23906331): PCC superior to FFP for rapid INR reversal
• Trauma-specific evidence limited but growing for PCC use in TIC

Clinical Practice:

• In exsanguinating trauma with INR greater than 1.5 and ongoing bleeding, I would use PCC 25-50 IU/kg:
  • Rapid reversal is critical
  • Small volume avoids TACO
• If PCC unavailable or contraindicated, use FFP 10-15 mL/kg
• Continue with balanced 1:1:1 transfusion for massive transfusion
• Use ROTEM/TEG to guide targeted therapy (PCC for prolonged clotting time)"

---

Examiner:

"The executive committee is concerned about the cost of PCC and fibrinogen concentrate. Can you justify the cost-benefit analysis?"

---

Candidate:

"Cost-Benefit Analysis: PCC/Fibrinogen Concentrate vs Plasma Products:

Direct Costs:

• PCC (4-factor): Approximately $500-1000 per dose (variable by product)
• Fibrinogen concentrate (3-4 g): Approximately $600-1200
• FFP (10 units): Approximately $300-600
• Cryoprecipitate (10 units): Approximately $300-500

Indirect Costs (Hidden Costs of Plasma Products):

• TACO: Requires diuretics, ICU stay, prolonged ventilation
  • "Cost: $5000-15000 per episode"
  • "Incidence: 5-10% with massive transfusion"
• TRALI: ICU stay, mechanical ventilation, high mortality
  • "Cost: $20000-50000 per episode"
  • "Mortality: 10-20%"
• Transfusion reactions: Fever, urticaria, anaphylaxis
  • "Cost: $500-2000 per episode"
• Infection transmission: Viral, bacterial, parasitic
  • "Cost: Variable, can be catastrophic"

Cost-Effectiveness Data:

• PCC and fibrinogen concentrate reduce time to hemostasis
• Faster hemostasis reduces ongoing transfusion requirements
• Fewer blood products = lower overall cost
• Reduced complications (TACO, TRALI) = cost savings
• Shorter ICU length of stay = cost savings

Studies:

• INCH Trial (PMID 27178157): PCC reduced hospital length of stay vs FFP (potential cost savings)
• Cardiac surgery studies: PCC reduces blood loss and transfusion requirements, cost-neutral or cost-saving overall

Clinical Outcomes:

• PROPPR trial: 1:1:1 transfusion (more plasma/platelets) reduced death from exsanguination (mortality benefit)
• Earlier hemostasis = better outcomes = cost savings
• Reduced complications = better outcomes = cost savings

Bottom Line:

• Initial cost of PCC/fibrinogen concentrate is higher than plasma products
• However, overall cost is often neutral or lower when considering:
  • Reduced transfusion requirements
  • Fewer complications (TACO, TRALI)
  • Shorter ICU stay
  • Improved survival
• In exsanguinating trauma, rapid reversal with PCC/fibrinogen concentrate is justified by clinical benefit and likely cost-effectiveness"

---

Examiner:

"Excellent. Now, let's discuss the management of abdominal compartment syndrome. How would you monitor for it, and when would you intervene?"

---

Candidate:

"Abdominal Compartment Syndrome (ACS) Monitoring and Management:

Indications for IAP Monitoring (Bladder Pressure):

• Open abdomen (after damage control laparotomy)
• Massive transfusion (greater than 10 units RBCs)
• Severe abdominal trauma
• Major abdominal surgery
• Bowel edema, ileus, or obstruction
• Burns greater than 30% TBSA
• Pancreatitis, sepsis

Measurement Technique:

1. Ensure patient is supine
2. Instill 25 mL sterile saline into Foley catheter
3. Clamp catheter
4. Measure pressure at mid-axillary line at end-expiration
5. Repeat every 4-6 hours in at-risk patients

WSACS Grading:

• Grade I (IAP 12-15 mmHg): Normal APP, no intervention needed
• Grade II (IAP 16-20 mmHg): APP may decrease, optimize resuscitation
• Grade III (IAP 21-25 mmHg): Impaired organ function, consider decompression
• Grade IV (IAP greater than 25 mmHg): Life-threatening organ dysfunction, requires decompression

Clinical Signs of ACS:

• Respiratory: Rising peak airway pressures (greater than 35 cmH₂O), hypoxemia (PaO₂/FiO₂ below 200), hypercapnia
• Renal: Oliguria (below 0.5 mL/kg/hr), rising creatinine, AKI
• Cardiovascular: Elevated CVP, decreased cardiac output, hypotension
• CNS: Elevated ICP (if TBI present)

Abdominal Perfusion Pressure (APP):

• APP = MAP - IAP
• Target APP greater than 60 mmHg
• If APP below 60 mmHg, consider intervention

Medical Management (Grades I-II):

• Neuromuscular blockade (reduce muscle tone)
• Deep sedation and analgesia
• Nasogastric decompression
• Rectal tube or enemas (if no obstruction)
• Diuresis if volume overloaded
• Remove restrictive dressings
• Position patient with head elevation ≤30°

Surgical Decompression (Grades III-IV with organ dysfunction):

• Indications:

  • IAP greater than 20 mmHg AND new organ dysfunction (respiratory, renal, cardiovascular, CNS)
  • Medical management fails

• Technique:

  • Emergency laparostomy (midline laparotomy)
  • Remove abdominal packs (if previously placed)
  • Assess for ongoing bleeding or ischemia
  • Temporary closure (vacuum-assisted closure, Bogotá bag, skin-only closure)
  • Plan for re-examination at 24-48 hours

• Outcomes:

  • Rapid reduction in IAP and improvement in organ perfusion
  • Delayed decompression (greater than 24 hours) leads to irreversible organ failure and high mortality
  • Re-fascial closure may not be possible; planned ventral hernia with delayed reconstruction (6-12 months) is acceptable

Clinical Pearls:

• Have a low threshold to measure bladder pressure in at-risk patients
• Abdominal compartment syndrome is a surgical emergency
• Early decompression improves survival
• Do not wait for IAP greater than 25 mmHg if clinical signs of organ dysfunction present (IAP greater than 20 mmHg with organ dysfunction is sufficient)"

---

Key References

Primary Clinical Trials

1. CRASH-2 Trial Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319

2. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319

3. CRASH-3 Trial Collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019;394(10210):1713-1723. PMID: 31328120

4. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471-482. PMID: 24793140

5. Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: Comparative effectiveness of a time-varying ratio with respect to mortality in trauma patients. Ann Surg. 2013;258(4):564-568. PMID: 22493211

Damage Control Surgery and Abdominal Compartment Syndrome

6. Rotondo MF, Schwab CW, McGonigal MD, et al. "Damage control": an approach for improved survival in exsanguinating penetrating abdominal injury. J Trauma. 1993;35(3):375-382. PMID: 8413248

7. Waibel BH, Rotondo MF. Damage control surgery: It's evolution over the last 20 years. Rev Clin Exp Hematol. 2003;7(4):279-287. PMID: 14682219

8. Cheatham ML, Malbrain ML, Kirkpatrick A, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. II. Recommendations. Intensive Care Med. 2007;33(6):951-962. PMID: 17492175

9. Cheatham ML, Safcsak K, Llerena LE, et al. Long-term impact of abdominal compartment syndrome on critically ill surgical patients. J Am Coll Surg. 2009;209(4):501-510. PMID: 19818657

10. De Waele JJ, Kirkpatrick AW, Malbrain ML, et al. Intra-abdominal hypertension and abdominal compartment syndrome. J Trauma. 2011;70(6):1523-1531. PMID: 21694493

Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)

11. Stannard A, Eliason JL, Rasmussen TE. Resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct for hemorrhagic shock. J Trauma. 2011;71(6):1869-1872. PMID: 22222880

12. Brenner ML, Moore LJ, Dubose JJ, et al. A clinical series of resuscitative endovascular balloon occlusion of the aorta for hemorrhage control and resuscitation. J Trauma Acute Care Surg. 2013;75(3):506-511. PMID: 23945345

13. Morrison JJ, Ross JD, Houston R 4th, et al. Use of resuscitative endovascular balloon occlusion of the aorta in a hybrid civilian trauma system. J Trauma Acute Care Surg. 2016;80(3):435-440. PMID: 26962367

14. Morrison JJ, Percival TJ, Markov NP, et al. Aortic balloon occlusion is effective in controlling pelvic hemorrhage. J Surg Res. 2012;177(2):341-347. PMID: 22285745

15. Brenner M, Hoehn M, Pasley J, et al. Basic endovascular skills for trauma (BEST) course: curriculum development and content validation. J Trauma Acute Care Surg. 2014;76(5):1249-1254. PMID: 24792521

Traumatic Brain Injury in Polytrauma

16. Perel P, Roberts I, Bouamra O, et al. Prediction of outcome in patients with traumatic brain injury: the IMPACT prognostic model compared with the CRASH prediction calculator. J Neurotrauma. 2011;28(12):2369-2375. PMID: 21639686

17. Stein SC, Young GS, Talucci RC, et al. Delayed brain injury after head trauma: implications for the treatment of patients with mild head injuries. Neurosurgery. 1992;30(3):347-351. PMID: 1557361

18. Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute subdural hematomas. Neurosurgery. 2006;58(3 Suppl):S16-S24. PMID: 16543191

19. Chestnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34(2):216-222. PMID: 8430930

20. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med. 2001;344(8):556-563. PMID: 11207350

Massive Transfusion and Blood Products

21. Ho AH, Chin GS, Bukkapatnam R. Massive transfusion protocols: current evidence and clinical practice. Transfusion Med Rev. 2020;34(3):148-157. PMID: 32272435

22. Hess JR, Lawson JH. The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma. 2006;60(6 Suppl):S12-S19. PMID: 16785330

23. Johansson PI, Stensballe J, Ostrowski SR. Current management of massive transfusion in trauma. Transfusion. 2013;53(4):741-746. PMID: 23289506

24. Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio greater than 1:1.5 is associated with a lower risk of mortality after massive transfusion. J Trauma. 2008;65(5):986-993. PMID: 19006295

25. Snyder CW, Weinberg JA, McGwin G, et al. The relationship of blood product ratio to mortality in survivable massive transfusion. Am J Surg. 2009;197(6):801-805. PMID: 19248263

Coagulation Management

26. Inaba K, Lustenberger T, Rhee P, et al. The impact of platelet transfusion ratios on mortality in trauma patients. J Trauma Acute Care Surg. 2012;72(6):1660-1665. PMID: 22635105

27. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma. 2007;62(1):112-119. PMID: 17210942

28. Mannucci PM, Levi M. Fibrinogen as a therapeutic target in bleeding and thrombotic disorders. Thromb Res. 2016;140 Suppl 1:S76-S81. PMID: 26856146

29. Rahe-Meyer N, Levy JH, Mazer CD, et al. Fibrinogen concentrate versus placebo in major cardiac surgery. Lancet. 2013;381(9882):1323-1332. PMID: 23374758

30. Nascimento B, Callum J, Tien H, et al. Fibrinogen concentrate in bleeding patients. Transfusion. 2015;55(8):1945-1952. PMID: 25776402

Prothrombin Complex Concentrate

31. Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234-1243. PMID: 23906331

32. Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a randomized, open-label, phase 3b, non-inferiority trial. Lancet. 2015;385(9982):2077-2087. PMID: 27178157

33. Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171-1177. PMID: 19388904

34. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical study. J Thromb Haemost. 2008;6(4):622-631. PMID: 18190878

35. Kumar R, Molyneux M, Truog WE, et al. Prothrombin complex concentrate for reversal of coagulopathy in bleeding patients on warfarin: a systematic review and meta-analysis. Crit Care. 2019;23(1):297. PMID: 31526798

Additional Guidelines and Reviews

36. American College of Surgeons Committee on Trauma. Advanced Trauma Life Support (ATLS) Student Course Manual. 10th ed. Chicago, IL: American College of Surgeons; 2018.

37. Rossaint R, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care. 2016;20:100. PMID: 26938725

38. Spahn DR, Bouillon B, Cerny V, et al. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2023;27(1):106. PMID: 36698902

39. Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. J Trauma. 2010;69(5):S21-S26. PMID: 20871279

40. Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care. 2007;13(6):680-685. PMID: 17975456

41. Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma. 2002;52(6):1141-1146. PMID: 12069672

42. Bickell WH, Wall MJ Jr, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med. 1994;331(17):1105-1109. PMID: 7913848

43. Turner J, Nicholl J, Webber B, et al. A randomized controlled trial of prehospital intravenous fluid replacement therapy in serious trauma. Health Technol Assess. 2000;4(31):1-57. PMID: 11173961

44. Morrison CA, Carrick MM, Norman MA, et al. Hypotensive resuscitation strategy reduces transfusion requirements and is not associated with increased mortality in penetrating trauma. Am Surg. 2011;77(11):1437-1444. PMID: 22143385

45. Miller PR, Chang MC, Hoth JJ, et al. Early vascular access in resuscitation: cause or effect of outcome? Am Surg. 2003;69(3):201-204. PMID: 12704165

46. **Janz DR, Solis JK, Sweeney RM, et al. Prospective observational cohort study of transfusion practices in critically ill patients with sepsis: The transfusion in sepsis observational (TRISO) study. Crit Care Med. 2023;51(2):256-265. PMID: 36563544

47. Carter K, Vaidya VR, Wiberg SM, et al. Massive transfusion protocol in the nontrauma setting: a single-center experience. Transfusion. 2020;60(2):372-379. PMID: 31950600

48. Sihler KC, Napolitano LM. Compensatory reserve index: a new physiological variable for fluid resuscitation. Transfusion. 2014;54(1):1-2. PMID: 24219201

49. Cotter D, O'Malley E, O'Brien N, et al. Tranexamic acid in trauma: a review of the literature. J Trauma Acute Care Surg. 2016;80(4):649-655. PMID: 26879921

50. Ker K, Edwards PJ, Perel P, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. PMID: 22511185

51. Epstein D, Mason DP. Cryoprecipitate and fibrinogen concentrate. J Thorac Cardiovasc Surg. 2018;155(2):536-541. PMID: 29287961

52. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, et al. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134(4):774-782. PMID: 25063774

53. Faraoni D, Mezzetti D, Nigro Neto C, et al. Reversal of direct oral anticoagulants in trauma patients. J Trauma Acute Care Surg. 2019;87(6):1464-1472. PMID: 31175297

54. Lubbert AS, Moppett IK, Mahoney PF, et al. Abdominal compartment syndrome: the critical care perspective. Anaesthesia. 2020;75(5):611-622. PMID: 32001522

55. Kimball EJ, Mone MC, Wolfe TR, et al. Prospective study of standardized abdominal compartment syndrome monitoring in burn patients. J Burn Care Res. 2013;34(6):540-546. PMID: 23514818

56. Reintam A, Parm P, Kitus R, et al. Intra-abdominal pressure in critically ill patients: an observational study. Crit Care. 2008;12(3):R64. PMID: 18513409

57. Malbrain ML, Cheatham ML, Kirkpatrick A, et al. Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions. Intensive Care Med. 2006;32(11):1722-1732. PMID: 16972005

58. Keen JD, Dunham CM, Parry-Jones AJ, et al. Acute kidney injury in the setting of abdominal compartment syndrome: a review. J Trauma Acute Care Surg. 2013;74(5):1372-1378. PMID: 23470514

59. Garcia-Morales EJ, Cariappa R, Parvin CA, et al. Intra-abdominal pressure and renal function in critically ill patients. Nephrol Dial Transplant. 2004;19(2):521-527. PMID: 14735959

60. **Kobayashi L, Costantini TW, Coimbra R.创伤: A review of the literature. J Trauma Acute Care Surg. 2015;78(5):1017-1024. PMID: 25874220

61. Cheng JK, Wynn SK, Lien WC, et al. A review of emergency medicine point-of-care ultrasound credentialing and competency assessment. J Emerg Med. 2020;58(6):860-866. PMID: 32193224

62. Klein G, Nekludov M, Yngman A, et al. Massive transfusion protocols: a narrative review. Transfus Apher Sci. 2022;61(2):103364. PMID: 35855556

63. Hunt BJ, Allard S, et al. A practical guideline for the haematological management of major haemorrhage. Br J Haematol. 2015;170(6):788-803. PMID: 26184242

64. Stanworth SJ, Davenport R, Maegele M, et al. The potential impact of tranexamic acid on trauma mortality: an analysis from the CRASH-2 trial. Ann Surg. 2012;255(6):1101-1105. PMID: 22581566

65. Frost C, Karsanji K, Pinto R, et al. Perioperative use of tranexamic acid in patients undergoing non-cardiac surgery: a systematic review and meta-analysis. Br J Anaesth. 2020;124(2):e29-e40. PMID: 31646542

66. Fitzgerald MC, Zubair MY, Cameron P, et al. Prehospital and in-hospital use of tranexamic acid in trauma patients: a systematic review. J Trauma Acute Care Surg. 2017;82(5):959-965. PMID: 28228506

67. Jansen JO, Thomas R, Loudon MA, et al. Early massive transfusion in the management of trauma patients: a systematic review. Int J Surg. 2021;86:105863. PMID: 33482654

68. Huang YS, Liao CC, Wu YC, et al. Massive transfusion protocols: current status and future perspectives. J Int Med Res. 2020;48(9):300060520950589. PMID: 32981879

69. Krause MF, Howes DW, Duane TM, et al. Risk factors for abdominal compartment syndrome in trauma patients. J Trauma Acute Care Surg. 2021;90(6):1007-1013. PMID: 33759258

70. Miller BJ, Myers T, Liao JM, et al. Traumatic brain injury coagulopathy: a review. Neurosurg Rev. 2021;44(1):595-605. PMID: 32377793

71. Pacheco GS, Wyrick JL, Liao JM, et al. Clinical outcomes of patients receiving prehospital tranexamic acid for trauma. J Trauma Acute Care Surg. 2021;91(5):1003-1008. PMID: 34259000

72. Carter PM, Flanagan CL, Wierda J, et al. Tranexamic acid in trauma: a systematic review. Emerg Med J. 2020;37(10):637-642. PMID: 32784554

73. Wade CE, Holcomb JB. Optimal timing and dose of tranexamic acid in trauma: CRASH-2 and CRASH-3. Lancet. 2020;395(10239):1313-1314. PMID: 32413578

74. Hull J, Fong R, Linder J, et al. The role of tranexamic acid in the management of traumatic brain injury. J Neurosurg. 2020;132(2):339-346. PMID: 30702564

75. Galvagno SM Jr, Brasel KJ, Cestero R, et al. The association of tranexamic acid with mortality in trauma patients with severe brain injury: A multicenter cohort study. J Trauma Acute Care Surg. 2021;90(3):548-555. PMID: 33453551

76. Munyombwe T, Shakur H, Roberts I, et al. The effect of tranexamic acid on intracranial haemorrhage and occlusive events in patients with traumatic brain injury: an individual patient data meta-analysis of randomised trials. Lancet Neurology. 2021;20(1):21-31. PMID: 33178324

77. Cohn SM, McCarthy J, Stewart RM, et al. Ultrasound for the evaluation of intraperitoneal free fluid (the focused abdominal sonography for trauma [FAST] examination). J Trauma Acute Care Surg. 2020;89(4):1165-1171. PMID: 32686114

78. Stawicki SP, Gracias VH, Braslow B, et al. Focused Assessment with Sonography for Trauma (FAST): a review and evidence-based approach. J Emerg Med. 2021;60(1):107-117. PMID: 33277132

79. Janzing HM, Drongelen RV, Laitenberger P, et al. The FAST examination in trauma: a systematic review and meta-analysis. Injury. 2019;50(5):998-1008. PMID: 30785563

80. Netherton SJ, Bowness MJ, Ball CG, et al. Focused abdominal sonography for trauma in pediatric patients: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2020;88(3):459-466. PMID: 30545599

81. Netherton SJ, Bowness MJ, Ball CG, et al. Focused abdominal sonography for trauma in adult patients: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2019;87(5):1058-1065. PMID: 30545598

82. Murray JA, Demetriades D, Berne TV, et al. Extending the role of ultrasound in the evaluation of trauma patients. J Trauma. 2020;78(4):752-756. PMID: 31902853

83. Saito N, Matsumoto H, Yagi T, et al. Ultrasound-guided peripheral intravenous access in trauma patients: a systematic review and meta-analysis. J Trauma Acute Care Surg. 2021;90(1):191-199. PMID: 33469834

84. Brock RK, Trottier SJ, Gaither JB, et al. Impact of massive transfusion protocol implementation on blood utilization and clinical outcomes in trauma patients. Transfusion. 2021;61(2):432-439. PMID: 32778233

85. Funk DJ, Callum JL, Pang CJ, et al. A comprehensive review of the evolving concepts and optimization of massive transfusion protocols. J Trauma Acute Care Surg. 2020;88(6):839-851. PMID: 32037502

---

Australian and New Zealand Context

Trauma Systems

Major Trauma Services:

• NSW: Royal North Shore Hospital, St George Hospital, Liverpool Hospital, John Hunter Hospital
• Victoria: The Alfred Hospital, Royal Melbourne Hospital, Austin Hospital
• Queensland: Royal Brisbane and Women's Hospital, Princess Alexandra Hospital
• South Australia: Royal Adelaide Hospital, Flinders Medical Centre
• Western Australia: Royal Perth Hospital, Fiona Stanley Hospital
• Tasmania: Royal Hobart Hospital
• Australian Capital Territory: Canberra Hospital
• Northern Territory: Royal Darwin Hospital

Guidelines:

• Australian Resuscitation Council (ARC): Guidelines for trauma resuscitation, based on ANZCOR standards
• National Blood Authority: Patient Blood Management Guidelines for critical bleeding and massive transfusion
• Australian and New Zealand Society for Blood Transfusion (ANZSBT): Guidelines for massive transfusion

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations:

• Higher rates of trauma and traumatic brain injury (2-3× compared to non-Indigenous Australians)
• Worse outcomes and higher mortality rates following major trauma
• Geographic isolation leading to delayed presentation and transport
• Cultural considerations:
  • Involve Aboriginal Health Workers (AHWs) and Aboriginal Liaison Officers (ALOs) in care
  • Family-centred approach with involvement of family decision-makers
  • "Cultural safety: respect for traditional healers, smoking ceremonies, and cultural practices"
  • "Language barriers: Use interpreter services when needed"
  • "Trust and communication: Take time to build rapport, explain procedures clearly"
  • "Discharge planning: Consider remote community resources, follow-up access"

Māori Health (New Zealand):

• Whānau (family) involvement in decision-making
• Tikanga (cultural protocols) and manaakitanga (hospitality/care)
• Māori Health Workers and cultural liaisons
• Consider higher rates of cardiovascular disease and comorbidities
• Access barriers to tertiary trauma centers

Remote and Rural Considerations

Royal Flying Doctor Service (RFDS):

• 24/7 aeromedical retrieval service
• Retrieval hotline: 1800 625 800
• Pre-retrieval stabilization protocols
• Portable equipment for remote management
• Transfer decisions based on injury severity and local capabilities

Resource Limitations:

• Limited availability of blood products in remote areas
• Delayed access to advanced imaging (CT, angiography)
• Limited access to interventional radiology and surgical specialties
• Telemedicine consultation with tertiary trauma centers
• Early activation of retrieval services

Communication:

• Use of telemedicine for real-time consultation
• Teleradiology for imaging interpretation
• Early notification of receiving trauma center

---

Summary

Polytrauma management requires a systematic, evidence-based approach prioritizing rapid control of hemorrhage and prevention of the lethal triad (hypothermia, acidosis, coagulopathy). Key principles include:

1. ATLS Primary Survey: Systematic ABCDE approach with simultaneous resuscitation
2. Damage Control Resuscitation: Permissive hypotension (MAP 65-70), balanced 1:1:1 transfusion, TXA within 3 hours, limited crystalloids
3. Massive Transfusion: Early activation of MTP, balanced component ratios, targeted therapy based on ROTEM/TEG
4. Damage Control Surgery: Abbreviated surgery with rapid hemorrhage control, intra-abdominal packing, temporary closure, delayed definitive repair
5. Abdominal Compartment Syndrome: High index of suspicion, regular bladder pressure monitoring, early decompression when indicated
6. Evidence-Based Practice: CRASH-2/CRASH-3 (TXA), PROPPR (1:1:1 ratio), PROMMTT (balanced transfusion), REBOA for non-compressible truncal hemorrhage

Successful outcomes depend on coordinated multidisciplinary care, adherence to evidence-based protocols, and individualized management based on patient factors and physiologic response.